LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.
Form:Solid
Specifiche
Specifiche e purezza
≥98%
Meccanismi biochimici e fisiologici
LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.
Condizioni di conservazione di stoccaggio
Protected from light,Store at -20°C,Desiccated
Spedito in
Ice chest + Ice pads
Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.
Purezza
≥98%
Nomi e identificatori
Peso molecolare
1044.22(free base)
Dati avanzati
Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Find and download the COA for your product by matching the lot number on the packaging.
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
Reconstitution Calculator
Recensioni
Recensioni dei clienti
Application Protocols
No item-specific, validated application protocols are provided in the Product Data. The following outlines general, literature-based procedures for peptide epitope use—adapt and validate for your system.
Example: Peptide pulsing of APCs for T cell activation (general)
Prepare a sterile peptide stock (e.g., 1–10 mM in DMSO or 0.1–1 mg/mL in PBS). Filter sterilize using a low-protein-binding 0.22 µm filter if needed.
Dilute peptide into serum-free medium to the desired pulsing concentration (optimize; typical ranges 10 nM–1 µM, system dependent).
Incubate APCs with peptide for 30–120 minutes at 37 °C, 5% CO2.
Wash cells to remove unbound peptide; proceed to co-culture with responder T cells.
Example: HPLC quality check (general)
Inject a small aliquot on a C18 column with a water/acetonitrile gradient (0.1% formic acid preferred for MS). Confirm the expected retention time and a single dominant peak if purity is high.
Controls and notes
Include vehicle controls matching DMSO content.
Titrate peptide concentration to establish EC50/functional range.
For MS assays, consider desalting to remove TFA.
Important: Treat these as starting points only. For item-specific recommendations (e.g., exact concentrations, validated readouts), refer to the CoA/Spec Sheet.
Biological Roles
General/literature context: LCMV gp33–41 denotes an immunodominant epitope within the lymphocytic choriomeningitis virus (LCMV) glycoprotein. Synthetic gp33–41 peptides are widely used as defined antigens in basic immunology research to study CD8+ T cell responses, antigen processing, and MHC class I presentation in murine systems.
Antigenicity: Short viral peptides (typically 8–10 residues) bind to MHC class I molecules, forming peptide–MHC complexes recognized by T cell receptors (TCRs) on cytotoxic T lymphocytes.
Model system relevance: LCMV is a foundational model in T cell biology, enabling investigations into memory formation, T cell exhaustion, and cross-priming (research context only). The gp33–41 epitope is among the most commonly employed synthetic peptides in this space.
Assay roles:
Functional readouts: IFN-γ ELISpot/ELISA, ICS for cytokines (e.g., IFN-γ, TNF-α), activation markers (CD69, CD25), degranulation (CD107a), and cytotoxicity assays.
Tetramer/Multimer technologies: Used to load MHC class I monomers for generating pMHC tetramers to enumerate antigen-specific T cells by flow cytometry (literature).
Biochemical studies: Employed to measure peptide–MHC binding kinetics, stability, and competition with endogenous peptides.
Important: The exact amino acid sequence and modifications for this catalog item are not specified here; consult the CoA/Spec Sheet for definitive identity before designing experiments.
Buffer Applications
This peptide reagent is typically reconstituted into aqueous buffers compatible with immunological and biochemical assays.
Stock preparation (general):
Start with sterile water, PBS (pH ~7.2–7.4), or assay buffer. If dissolution is incomplete, pre-wet with minimal DMSO or use dilute acid/base depending on net charge (sequence-dependent; not specified for this item).
Typical stock concentrations: 1–10 mM in DMSO or 0.1–1 mg/mL in aqueous buffer (optimize empirically for your assay; literature guidance only).
Working buffers:
Cell-based assays: Serum-containing RPMI/DMEM with peptide added shortly before use to minimize adsorption and degradation.
MHC binding assays: Use defined buffers (e.g., PBS with stabilizing proteins) and maintain neutral pH.
MS workflows: Favor volatile buffers (e.g., 0.1% formic acid or ammonium acetate); consider desalting to remove TFA for improved ionization.
Additives (if compatible):
0.1% BSA or 0.01–0.1% Tween-20 can reduce surface adsorption in low-concentration applications; verify that additives do not interfere with readouts.
Filtration/sterility:
Use 0.22 µm low-protein-binding filters for sterility when needed; confirm recovery as some membranes bind peptides.
Storage of solutions:
Aliquot immediately after reconstitution; store at −20 °C to −80 °C. Avoid repeated freeze–thaw. Include date, concentration, and solvent on labels.
Note: No formal buffering capacity is attributed to the peptide; buffer selection is driven by the downstream biological assay.
Green Alternatives
While “green chemistry” considerations are less central for a small-quantity peptide reagent, the following choices can reduce environmental impact without compromising performance.
Counterion considerations:
TFA salts are common from RP-HPLC purification but can hinder MS sensitivity and add halogenated waste. If greener profiles are desired, consider exchanging to acetate or chloride via desalting (post-purchase lab operation; item is supplied as TFA).
Solvent choices:
Prefer water or aqueous buffers as primary solvents. Limit DMSO volumes to the minimum required for dissolution.
Avoid halogenated solvents; peptides rarely need them. For MS workflows, volatile acids (formic acid) are friendlier than TFA for ionization efficiency.
Process minimization:
Prepare concentrated stocks to reduce container usage and shipping frequency.
Use low-binding plastics to minimize losses and rework.
Comparison (general):
TFA salt vs acetate salt:
TFA: robust purification, strong ion pairing; potential MS suppression and halogenated waste.
Acetate: more benign waste stream; often similar solubility; may require optimization of handling due to weaker ion pairing.
Waste handling:
Collect TFA-containing aqueous waste separately if your institution treats halogenated waste distinctly.
Favor on-demand preparation to minimize expired materials.
Note: The supplied form of this item is TFA; any counterion exchange would be performed by the end user based on application needs.
Pharmaceutical Uses
This product is offered strictly for research use only. It is not intended for human or veterinary use, diagnostic procedures, or as an active pharmaceutical ingredient.
Within a laboratory and manufacturing development context (non-clinical):
Reference/assay standard: Synthetic peptides like LCMV gp33–41 may be used as process controls or system suitability standards in analytical methods (e.g., LC–MS retention time or response checks) during method development.
Device/assay development research: Employed in preclinical research to develop and benchmark immunoassays, pMHC tetramer generation workflows, and T cell activation readouts.
Excipients/status: No pharmacopeial excipient role is associated with this item. It is not an approved excipient and carries no compendial monograph.
Regulatory cautions:
Not GMP grade unless explicitly stated (not specified for this item; refer to CoA/Spec Sheet).
For any translational research or regulated studies, verify grade, documentation, and impurity profile suitability, and perform risk assessments for residual TFA and synthesis reagents.
In summary, use this peptide as a research reagent to support assay development and basic science. Do not incorporate into clinical formulations or therapeutic studies.
Physical Properties
Item-specific physicochemical constants are not provided in the product data. For rigorous experimental planning, please consult the item’s CoA/Spec Sheet.
Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
Appearance: Not specified for this item; refer to CoA/Spec Sheet.
pKa values: Sequence-dependent (multiple ionizable groups in peptide termini and side chains); not specified for this item.
Solubility (general guidance for peptide TFA salts; literature/general knowledge):
Frequently soluble in water, aqueous buffers (pH-dependent), and polar organics like DMSO.
Initial dissolution can be improved with a small volume of neat DMSO or dilute aqueous base/acid before diluting into assay buffer.
Avoid high-pH exposure if sequence is oxidation-prone (e.g., Cys, Met side chains; sequence for this item not specified).
Hygroscopicity: Many peptide TFA salts are mildly hygroscopic (general); minimize atmospheric exposure during weighing.
Stability (general): Lyophilized peptides are typically stable when stored desiccated at ≤ −20 °C and protected from light; repeated freeze–thaw cycles in solution can degrade peptides.
Optical properties: Aromatic residues (if present) contribute to UV absorbance near 214 nm (peptide bond) and ~280 nm (Trp/Tyr/Phe; sequence not specified for this item). Use these wavelengths cautiously for quantitative assays.
Note: Do not treat the above as item specifications; these are general, literature-based characteristics of short peptide TFA salts.
Quality and Grades
Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet. For peptide reagents, purity is commonly reported by analytical HPLC (area %) and supported by MS/HRMS; confirm on the supplied documentation.
TFA enhances salt formation and often improves aqueous solubility.
Residual TFA can suppress certain enzyme activities and can interfere with cell culture at elevated concentrations; consider buffer exchange or neutralization if required for sensitive applications.
Identity testing (typical for peptides; general): ESI/ MALDI-MS for exact mass; HPLC for purity profile; optional amino acid analysis or sequencing for confirmation when critical.
Endotoxin/bioburden: Not specified for this item. If low endotoxin is needed for immune cell assays, request or perform endotoxin testing.
Batch documentation: Each lot should be accompanied by a CoA detailing sequence, counterion form, purity, and analytical methods. Use the CoA as the controlling document for acceptance criteria.
Use case alignment:
Analytical/assay standard: Prioritize high HPLC purity and verified identity.
Cellular assays: Prefer low residual solvents/reagents; consider desalting if TFA-sensitive.
In vivo research: Not covered by this listing; this product is for research use only and not for use in animals or humans.
Note: Where specific numeric specifications are required (purity %, water content, residual solvents, metal content), these are Not specified for this item; refer to CoA/Spec Sheet.
Reaction and Applications
Chemical reaction applications are not typically the focus for a defined viral epitope peptide. Instead, this reagent is primarily used as a functional tool in immunology and biochemical assays (research use only).
Relevant research applications (general/literature):
Antigen-specific T cell assays: Stimulate and detect peptide-responsive CD8+ T cells in murine systems using peptide-loaded antigen-presenting cells (APCs) for ELISpot, intracellular cytokine staining (ICS), or flow cytometric activation markers.
MHC binding studies: Quantify peptide–MHC class I complex stability and affinity using refolded MHC or cell-based binding assays.
Positive control in assay development: Benchmark processing-independent recognition in experiments dissecting TCR signaling, costimulation, and checkpoint pathways.
Quantitative LC–MS standards: Use as a reference peptide for retention time calibration or method development (with caveats regarding TFA counterion; consider desalting for MS sensitivity).
Practical tips:
Prepare fresh working solutions; aliquot and store at −20 °C to avoid repeated freeze–thaw.
Validate the effective working concentration empirically (typical working ranges in T cell assays are in the low nanomolar to micromolar, depending on system—optimize per setup; literature guidance only).
Ensure sterility for cell-based assays via sterile filtration (use low-protein-binding membranes) or prepare under aseptic conditions.
Note: No named organic reactions or catalytic transformations are typically associated with this peptide reagent.
Reaction Conditions
Classical organic reaction conditions do not generally apply to a peptide epitope reagent. The relevant “conditions” pertain to dissolution, handling, and use in bioassays.
General guidance (literature/practice):
Reconstitution: Bring vial to room temperature in a desiccator; briefly centrifuge to collect material at the bottom before opening. Dissolve in sterile water, PBS, or minimal DMSO as needed, then dilute to the desired concentration.
Working concentrations: Optimize empirically for your assay. In many T cell stimulation assays, effective concentrations can span from low nanomolar to micromolar depending on APC expression and readout sensitivity (literature guidance only; not item-specific).
Incubation parameters for cell assays (general):
Pulse APCs with peptide for 30–120 minutes at 37 °C, wash to remove excess peptide, and proceed to co-culture with T cells.
For direct addition to co-cultures, minimize DMSO to ≤0.1% v/v to avoid cytotoxicity.
Stability in solution: Use freshly prepared solutions or aliquots stored at −20 °C to −80 °C. Avoid >3–4 freeze–thaw cycles. Protect from light.
Analytical conditions: For RP-HPLC, peptides commonly elute on C18 with water/acetonitrile gradients containing 0.1% formic or TFA; for MS detection, avoid TFA or perform post-column addition strategies to mitigate ion suppression.
Note: The above are general best practices and not specifications for this item. Always validate in your specific system.
Safety and Handling
Safety information specific to this catalog item is not provided in the Product Data. Always review the SDS for authoritative guidance.
GHS classification, pictograms, H-statements: Not specified for this item; refer to SDS.
General hazard profile (peptides): Typically low volatility solids with low acute toxicity by inhalation; primary risks are dust generation, skin/eye irritation, and sensitization in susceptible individuals (general/literature). Avoid aerosolization.
Recommended PPE: Lab coat, gloves (nitrile), safety glasses. Use a balance enclosure or fume hood when weighing to minimize airborne particulates.
Handling tips:
Work quickly with the vial open; peptide TFA salts can be mildly hygroscopic.
Allow vial to equilibrate to room temperature in a desiccator before opening to prevent condensation.
Use sterile, low-protein-binding plasticware for biological assays to minimize adsorption losses.
Incompatibilities (general): Strong oxidants; prolonged exposure to strong acids/bases may cause hydrolysis or side-chain modification. Avoid light if sequence contains photosensitive residues (general precaution).
First-aid overview (general):
Inhalation: Move to fresh air; seek medical attention if symptoms persist.
Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; obtain medical advice if irritation persists.
Ingestion: Rinse mouth; seek medical attention. Do not induce vomiting unless directed by medical personnel.
Waste: Dispose of peptide solutions and contaminated materials according to institutional and local regulations for non-halogenated organic/aqueous laboratory waste.
Solvent Selection
This item is a short synthetic peptide provided as a TFA salt. Solvent choice should prioritize complete dissolution, chemical stability, and compatibility with the downstream assay.
Polarity/miscibility (general):
High polarity; readily hydrated. Frequently soluble in water, PBS, or assay buffers. If initial dissolution is incomplete, use a minimal volume of DMSO or dilute acid/base to assist, then dilute with buffer.
DMSO is fully miscible with water and is widely used for preparing high-concentration peptide stocks.
Practical dissolution workflow (general best practice):
Warm buffer to room temperature; briefly sonicate if permitted.
Wet the peptide with a small volume (e.g., 10–50 µL) of DMSO or 0.1% aqueous TFA or dilute NH4OH, depending on net charge at working pH (sequence-dependent; not specified for this item).
Bring to final volume with buffer; vortex and, if needed, brief bath sonication.
Clarify by low-speed spin; avoid filter membranes that bind peptides unless validated as low-binding.
Buffer selection:
For immunological assays, neutral pH buffers (PBS, HBSS) are common; avoid excessive TFA carryover.
For mass spectrometry, volatile buffers (0.1% formic acid or ammonium acetate) are preferred; TFA can suppress ionization—consider desalting or exchanging counterions.
Stability considerations:
Avoid prolonged exposure to high pH (>9) or high temperature.
Add carrier protein (e.g., 0.1% BSA) or 0.01–0.1% Tween-20 only if compatible with the assay to reduce adsorption losses (general).
Storage and Reconstitution
Follow best practices for peptide handling to preserve integrity and performance.
Item-specific storage (from Product Data):
Storage conditions: Protected from light, store at −20 °C, desiccated.
Shipped in: Ice chest + ice pads.
Reconstitution (general guidance):
Before opening: Allow vial to equilibrate to room temperature in a desiccator. Briefly spin down to collect contents.
Solvent choice: Start with sterile water or buffer (e.g., PBS). If incomplete dissolution occurs, pre-wet with a minimal volume of DMSO or adjust pH modestly with dilute acid/base according to the peptide’s net charge (sequence-dependent; not specified for this item).
Concentration: Prepare a concentrated stock appropriate for your assays (commonly 1–10 mM in DMSO or 0.1–1 mg/mL in aqueous buffer; literature guidance only). Document exact concentration based on accurate weighing and solvent volume.
Aliquoting and stability:
Aliquot immediately after reconstitution to single-use volumes.
Store aliquots at −20 °C to −80 °C. Avoid repeated freeze–thaw cycles; discard aliquots if turbidity, precipitation (in fully miscible systems), or unexpected assay behavior is observed.
Protect from light during storage and handling.
Thawing and use:
Thaw on ice or at room temperature depending on solvent; mix gently. Use promptly, then refreeze unused aliquots once only if unavoidable.
Note: Appearance, exact solubility, and concentration limits are Not specified for this item; refer to CoA/Spec Sheet for lot-specific details.
Structure and Identity
A research-grade peptide corresponding to the LCMV glycoprotein epitope spanning residues 33–41, provided as the trifluoroacetate (TFA) salt.
SKU: L650674
Product name: LCMV gp33-41 TFA
CAS: 151705-84-9 (free base)
Category: Small molecules and compound library (peptide epitope)
Counterion/form: Trifluoroacetate (TFA) salt of the peptide
Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
SMILES: Not specified for this item; refer to CoA/Spec Sheet.
InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
Structural features (general, peptide epitope):
Linear, short peptide (classically a nonapeptide epitope) derived from the LCMV glycoprotein region 33–41 (literature). Specific sequence for this item is not provided here; consult the CoA for confirmation.
Composed of standard α-amino acids with peptide (amide) bonds linking the residue backbone (–NH–CH(R)–CO–).
Possesses terminal functionalities typical of synthetic peptides (free or protected termini depending on synthesis; item-specific termini state not provided).
TFA counterions balance cationic sites and can influence solubility and pH upon dissolution.
2D structural description (general):
Repeating –NH–C(=O)– motif along the backbone with side chains (R groups) projecting alternately, enabling MHC class I peptide binding in immunological assays (literature). No ring systems are intrinsic to the backbone; side chains may include aliphatic or aromatic groups depending on the exact sequence (not specified for this item).
Synthetic Utility
As a defined viral epitope peptide, this product is not typically used as a building block in multistep organic synthesis. However, it has significant utility as a defined molecular probe in biochemical method development.
Not a general-purpose reagent for organic transformations. No named reactions are associated with this peptide in synthetic chemistry workflows.
Utility in analytical chemistry:
Serves as a calibration/benchmark analyte for HPLC/UPLC method development on reversed-phase columns (peptide elution behavior, gradient optimization).
Useful for testing sample preparation protocols (desalting, SPE recovery, membrane binding), enabling optimization with a peptide-like analyte.
Peptide chemistry relevance (general):
If engaging in custom peptide conjugation (e.g., fluorescent labeling, biotinylation), standard N-hydroxysuccinimide (NHS) ester strategies or click-compatible handles can be applied, provided the sequence contains the requisite functional groups (not specified for this item). Any modification would be end-user-performed and is not part of this supplied reagent.
If your goal is classical synthetic chemistry (e.g., cross-coupling, Grignard, reductions), this item is not applicable. Instead, leverage it for biological assay development and analytical validation where a well-characterized, short peptide standard is advantageous.
Target Specificity
Item-specific target reactivity and validated targets/applications are not provided in the Product Data.
Target name/antigen, epitope mapping, species reactivity: Not specified for this item; refer to CoA/Spec Sheet.
Literature context (for background only, not item-specific): LCMV gp33–41 peptides are classically used as immunodominant epitopes in murine T cell research. However, do not infer target specificity for this item without verifying the exact sequence and assay validations on the supplied documentation.
For definitive target specificity and validated uses, consult the lot-specific CoA and any associated technical notes.
Domande frequenti
What is the purity of this product?
This product is supplied at ≥98% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.
How should this product be stored?
Store at ?20 °C, protected from light, desiccated. Keep the container tightly closed with desiccant — the material is moisture-sensitive.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 151705-84-9(free base), the molecular formula is C48H73N11O13S(free base), and the molecular weight is 1044.22(free base) g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.
Utilizziamo i cookie per garantire il corretto funzionamento del sito web e, ove consentito, per migliorare la tua esperienza. Puoi gestire le tue preferenze in qualsiasi momento nelle Impostazioni. Per saperne di più, consulta la nostra Cookie Policy.
Desidera che le inviamo un messaggio quando avremo sconti disponibili?
Ricordamelo più tardi
Grazie! Controlli la sua casella di posta per confermare.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
H2515562